The European Commission (EC) has approved Bavencio (avelumab) as a first-line maintenance treatment for adults with advanced urothelial carcinoma, the most common form of bladder cancer, whose disease did not progress after platinum-based chemotherapy. This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency. Bavencio was approved in the U.S. for the same indication in June 2020. “Today’s announcement is the latest example of our…

You must be logged in to read/download the full post.